India, July 2 -- Abeona Therapeutics Inc. (ABEO) has completed the sale of its Rare Pediatric Disease Priority Review Voucher or PRV for gross proceeds of $155 million, finalizing the transaction on June 27, 2025.

With the proceeds from the PRV sale, the company estimates its unaudited cash, cash equivalents, restricted cash, and short-term investments totaled approximately $225 million as of June 30, 2025.

Chief Financial Officer Joe Vazzano noted that the sale marks a key milestone, securing more than two years of operating capital without requiring additional funding, even before accounting for revenue from ZEVASKYN. The company expects to begin treating the first ZEVASKYN patient in Q3 2025 and anticipates reaching profitability in ea...